NRAS and leukemia: In mutation models, anti-PD-1 treatment has limited effect on relieving T cell suppression and the recovery of anti-leukemia immune responses is also limited, suggesting that NRAS mutant AML evades immune system surveillance through multiple mechanisms (89).